Lysogene

81 articles about Lysogene

• Lysogene Receives FDA Fast Track Designation for LYS-SAF302 Gene Therapy in MPS IIIA

  2/25/2020

  Lysogene announced that the U.S. Food and Drug Administration has granted Fast Track Designation to its LYS-SAF302 program for the treatment of mucopolysaccharidosis Type IIIA.

• Lysogene Reports its Cash Position as of 31 December 2019

  2/17/2020

  Lysogene, a pioneering Phase 3 biopharmaceutical company specializing in gene therapy targeting central nervous system diseases, reports its cash position as of 31 December 2019.

• Lysogene Announces Presentations at Upcoming 16th WORLDSymposium™ on Lysosomal Diseases

  2/11/2020

  Lysogene announced its participation to the upcoming 16th WORLDSymposium™ on Lysosomal Diseases to be held February 10 – 13, 2020 in Orlando, FL, USA.

• Lysogene Announces Its Corporate Agenda For 2020

  1/24/2020

  Reminder of the other communications expected in the 1st Half of 2020

• Lysogene Announces the Publication of an Article in the Scientific Journal "Molecular Therapy Methods & Clinical Development” Demonstrating the Potential of Its Drug Candidate LYS-SAF302

  12/18/2019

  Lysogene (Paris:LYS) (FR0013233475 – LYS), a pioneering Phase 3 biopharmaceutical company specializing in gene therapy targeting central nervous system (CNS) diseases, today announced the publication of a scientific article describing preclinical work performed with LYS-SAF302, a drug candidate currently in a phase II/III clinical trial (NCT03612869) for the treatment of Mucopolysaccharidosis Type IIIA (MPS IIIA) disease.

• Lysogene Reports its Cash Position as of 30 September 2019

  11/20/2019

  Lysogene, a pioneering Phase 3 biopharmaceutical company specializing in gene therapy targeting central nervous system diseases, reports its cash position as of 30 September 2019.

• Lysogene Appoints Mr. Stéphane Durant des Aulnois as Chief Financial Officer

  10/17/2019

  Lysogene (Paris:LYS) (FR0013233475 – LYS), a pioneering Phase 3 biopharmaceutical company specializing in gene therapy targeting central nervous system (CNS) diseases, today announced the appointment of Stéphane Durant des Aulnois as Chief Financial Officer

• Lysogene Reports First Half 2019 Financial Results and Provides Operational Update

  9/30/2019

  Lysogene, a pioneering, Phase 3, biopharmaceutical company specializing in gene therapy targeting central nervous system diseases, announced financial results and major advancements for 2019.

• Lysogene Announces the Appointment of Carole Deffez as New Independent Board Director

  9/26/2019

  Lysogene announced that it is expanding its Board of Directors through the appointment of Carole Deffez as independent Director.

• Lysogene: A Pivotal Year 2019 for Lysogene’s MPS IIIA Phase 2-3 Clinical Trial

  9/5/2019

  Lysogene (FR0013233475 – LYS) (Paris:LYS), a pioneering biopharmaceutical company specializing in gene therapy targeting central nervous system (CNS) diseases, today announced major advancements, for their Sanfilippo syndrome type A (MPS IIIA) clinical program.

• Lysogene Establishes Scientific Advisory Board with International Experts in CNS Gene Therapy

  7/18/2019

  Lysogene (Paris:LYS) (FR0013233475 – LYS), a leading, Phase 3, biopharmaceutical company pioneering gene therapy technologies to treat central nervous system (CNS) diseases, today announced the formation of a Scientific Advisory Board (SAB) comprised of world-leading experts in gene therapy discovery and development

• Sarepta and Lysogene Announce Exclusive License Agreement for LYS-SAF302, a Late-stage Gene Therapy for the Treatment of MPS IIIA, and Grant of Option Rights to an Additional CNS Gene Therapy Candidate

  10/15/2018

  Expands Sarepta’s portfolio to as many as 14 gene therapy programs

• Lysogene Announces FDA approval of IND Application to Initiate Phase 2-3 Clinical Trial in MPS IIIA

  9/5/2018

  Novel, one-time, investigational gene therapy treatment for MPS IIIA focused toward preventing neurocognitive decline

• 

  Lysogene Pushes Forward With Sanfilippo Syndrome Study, Establishes Footprint in U.S.

  10/25/2017

  Finding a treatment for Sanfilippo Syndrome is a personal matter for the Lysogene team.

• Lysogene Announces Company Presentations At Upcoming Scientific Conferences

  10/18/2017

  Lysogene, a leading, biopharmaceutical company pioneering gene therapy technologies to treat central nervous system diseases, today announced that it will be participating in and presenting at several scientific events in the upcoming weeks.

• Lysogene To Host Key Opinion Leader Meeting On Gene Therapy For Patients With Sanfilippo Syndrome Type A In New York City

  10/6/2017

• Lysogene Announces Company Presentations At October & November Investor Conferences

  10/5/2017

• Lysogene Announces Company Presentations At October & November Investor Conferences

  10/5/2017

• Lysogene Holds First Parent Advisory Board In MPS IIIA

  9/21/2017

• Lysogene Launches World Class Clinical Advisory Board

  9/12/2017